A short-acting insulin secretogue.
Assignment of this agent for 5 years did not reduce the incidence of diabetes or cardiovascular outcomes among persons with impaired glucose tolerance with established cardiovascular disease or cardiovascular risk factors (NAVIGATOR Study Group).